Skip to main content
Erschienen in: Supportive Care in Cancer 5/2009

01.05.2009 | Original Article

Symptom distress in advanced cancer patients with anxiety and depression in the palliative care setting

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Mood disorders are among the most distressing psychiatric conditions experienced by patients with advanced cancer; however, studies have not shown a direct association of physical symptoms with depression and anxiety.

Purpose

The purpose of this study is to determine the relationship between the frequency and intensity of patients’ physical symptoms and their expressions of depression and anxiety.

Patients and methods

We retrospectively reviewed the records of 216 patients who had participated in three previous clinical trials conducted by our group. We assessed patients’ demographic data using descriptive statistics. We analyzed physical symptom frequency and intensity using the Edmonton Symptom Assessment System (ESAS) and anxiety and depression using the respective subscales of the Hospital Anxiety and Depression Scale (HADS-A and HADS-D).

Results

Sixty-two percent were male; the median age was 59 years (range 20–91 years). Seventy nine (37%) of the patients had depressive mood (HADS-D ≥ 8), and 94 (44%) had anxiety (HADS-A ≥ 8). Patients with depressive mood expressed higher frequency of drowsiness (68/78, 64%; p = 0.0002), nausea (52/79, 66%; p = 0.0003), pain (74/79, 94%; p = 0.0101), dyspnea (68/79, 86%; p = 0.0196), worse appetite (72/79, 91%; p = 0.0051), and worse well-being (78/79, 99%; p = 0.0014) and expressed higher intensity of symptoms (ESAS ≥ 1) [median (Q1–Q3)] including drowsiness [4 (3–7), p = 0.0174], fatigue [7 (5–8), p < 0.0001], and worse well-being [6 (5–7), p < 0.0001]. Patients with anxiety expressed higher frequency of nausea (59/94, 57%; p = 0.0006), pain (88/94, 89%; p = 0.0031), and dyspnea (84/94, 96%, p = 0.0002) and expressed a higher intensity of pain [6 (3–8), p = 0.0082], fatigue [6 (5–8), p = 0.0011], worse appetite [6 (4–8), p = 0.005], and worse well-being [5 (3–7), p = 0.0007]. Spearman’s correlation showed a significant association between HADS-A and HADS-D and other symptoms in the ESAS. Spearman’s correlations of HADS with ESAS-Anxiety and ESAS-Depression were 0.56 and 0.39, respectively (p < 0.001).

Conclusion

Expression of physical symptoms may vary in frequency and intensity among advanced cancer patients with anxiety and depression. Patients expressing high frequency and intensity of physical symptoms should be screened for mood disorders in order to provide treatment for these conditions. More research is needed.
Literatur
3.
Zurück zum Zitat Asbury FD, Madlensky L, Raich P et al (2003) Antidepressant prescribing in community cancer care. Support Care Cancer 11:278–285 Asbury FD, Madlensky L, Raich P et al (2003) Antidepressant prescribing in community cancer care. Support Care Cancer 11:278–285
4.
Zurück zum Zitat Block S (2000) Assessing and managing depression in the terminally ill patient. Ann Intern Med 32:209–218 Block S (2000) Assessing and managing depression in the terminally ill patient. Ann Intern Med 32:209–218
5.
Zurück zum Zitat Bruera E, Kuehn N, Miller M, Selmser P, Macmillan K (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed Bruera E, Kuehn N, Miller M, Selmser P, Macmillan K (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed
9.
11.
Zurück zum Zitat Holland JC, Jacobsen PB, Riba MB (2001) NCCN distress management. Cancer Control 8(6):88–93PubMed Holland JC, Jacobsen PB, Riba MB (2001) NCCN distress management. Cancer Control 8(6):88–93PubMed
14.
Zurück zum Zitat Komaroff AL (2001) Symptoms: in the head or in the brain? Ann Intern Med 134:783–785PubMed Komaroff AL (2001) Symptoms: in the head or in the brain? Ann Intern Med 134:783–785PubMed
17.
18.
Zurück zum Zitat Love A, Grabasch B, Clarke D, Bloch S, Kissane D (2004) Screening for depression in women with metastatic breast cancer: a comparison of the beck depression inventory short form and the hospital anxiety and depression scale. Aust N Z J Psychiatry 38:526–531. doi:10.1111/j.1440-1614.2004.01385.x PubMedCrossRef Love A, Grabasch B, Clarke D, Bloch S, Kissane D (2004) Screening for depression in women with metastatic breast cancer: a comparison of the beck depression inventory short form and the hospital anxiety and depression scale. Aust N Z J Psychiatry 38:526–531. doi:10.​1111/​j.​1440-1614.​2004.​01385.​x PubMedCrossRef
21.
Zurück zum Zitat Massie MJ (2000) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 32:57–71 Massie MJ (2000) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 32:57–71
24.
Zurück zum Zitat Olsson I, Mylketun Am Dahl Alv A (2005) The hospital anxiety and depression rating scale: a cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry 5:46. doi:10.1186/1471-244X-5-46 PubMedCrossRef Olsson I, Mylketun Am Dahl Alv A (2005) The hospital anxiety and depression rating scale: a cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry 5:46. doi:10.​1186/​1471-244X-5-46 PubMedCrossRef
27.
Zurück zum Zitat Perry MC (ed) (2000) An algorithm for rapid assessment and referral of distressed patients. American Society of Clinical Oncology, Alexandria Perry MC (ed) (2000) An algorithm for rapid assessment and referral of distressed patients. American Society of Clinical Oncology, Alexandria
31.
Zurück zum Zitat Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E (2004) Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 100:851–858. doi:10.1002/cncr.20028 PubMedCrossRef Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E (2004) Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 100:851–858. doi:10.​1002/​cncr.​20028 PubMedCrossRef
32.
Zurück zum Zitat Reddy S, Elsayem A, Palmer L, Kaur G, Zhang T, Bruera E (2005) The characteristics and correlates of dyspnea (D) in advanced cancer patients. J Clin Oncol 23:8019, ASCO Annual Meeting Proceedings [Abstract #8019 (poster discussion)] Reddy S, Elsayem A, Palmer L, Kaur G, Zhang T, Bruera E (2005) The characteristics and correlates of dyspnea (D) in advanced cancer patients. J Clin Oncol 23:8019, ASCO Annual Meeting Proceedings [Abstract #8019 (poster discussion)]
33.
Zurück zum Zitat Rees E, Hardy J, Ling J, Broadley K, A’Hern R (1998) The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliat Med 15:213–214 Rees E, Hardy J, Ling J, Broadley K, A’Hern R (1998) The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliat Med 15:213–214
39.
Zurück zum Zitat Teunissen SCCM, de Graeff A, Voest EE, de Haes JCJM (2007) Are anxiety and depressed mood related to physical symptom burden? A study in hospitalized advanced cancer patients. Palliat Med 21:341–346. doi:10.1177/0269216307079067 PubMedCrossRef Teunissen SCCM, de Graeff A, Voest EE, de Haes JCJM (2007) Are anxiety and depressed mood related to physical symptom burden? A study in hospitalized advanced cancer patients. Palliat Med 21:341–346. doi:10.​1177/​0269216307079067​ PubMedCrossRef
Metadaten
Titel
Symptom distress in advanced cancer patients with anxiety and depression in the palliative care setting
Publikationsdatum
01.05.2009
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0529-7

Weitere Artikel der Ausgabe 5/2009

Supportive Care in Cancer 5/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.